Biopharmaceutical benchmarks 2010
- G. Walsh
- BiologyNature Biotechnology
- 1 September 2010
Over the past four years, several new types of experimental biologic treatment have received commercial registration, but the emergence of biosimilars represents the biggest shift in the biologic…
Biopharmaceutical benchmarks 2014
- G. Walsh
- BiologyNature Biotechnology
- 9 October 2014
Monoclonal antibodies continue their march on the markets, optimized so-called biobetter versions of existing biologics are also gaining ground, but the rate of biosimilar approvals has seen a…
Post-translational modifications in the context of therapeutic proteins
- G. Walsh, R. Jefferis
- BiologyNature Biotechnology
- 1 October 2006
A better understanding of the relationship between structure and function is understood for many PTMs but remains incomplete for others, particularly in the case of complex PTMs, such as glycosylation.
Biopharmaceutical benchmarks 2018
- G. Walsh
- BiologyNature Biotechnology
- 1 December 2018
Monoclonal antibodies (mAbs) continue to reign supreme, although cellular and gene therapies are slowly starting to gather momentum. Burgeoning growth in biosimilars may threaten future brand…
Biopharmaceutical benchmarks
- G. Walsh
- Biology, MedicineNature Biotechnology
- 2000
Less than 20 years after the first biopharmaceutical, insulin, was approved, a new generation of products is superseding replacement proteins and enzyme therapies in biotechnology's pipeline.
Post-translational modifications of protein biopharmaceuticals.
- G. Walsh
- BiologyDrug Discovery Today
- 15 April 2009
Proteins: Biochemistry and Biotechnology
- G. Walsh
- Biology
- 5 December 2001
This chapter discusses the purification and characterization of therapeutic proteins, as well as industrial enzymes, of blood products and vaccines, and the role of proteases in this process.
Biopharmaceutical benchmarks 2006
- G. Walsh
- Biology, MedicineNature Biotechnology
- 1 July 2006
The rate of biopharmaceutical approvals has leveled off, but some milestones bode well for the future.
Production, purification and application-relevant characterisation of an endo-1,3(4)-β-glucanase from Rhizomucor miehei
The enzyme was found to be more thermostable than current commercialized β-glucanases, particularly when heated at a high enzyme concentration, and retained twice as much residual activity as the latter upon exposure to simulated avian digestive tract conditions.
...
...